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Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment. Recently, two immune
checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy. Their antitumor efficacy has been
confirmed by in vitro and in vivo studies. But the correlation between PD-1/PD-L1 expression and EGFR expression was
controversial and needs more evidences to support the combination of PD-1/PD-L1 inhibitors and tyrosine kinase
inhibitors.
Keywords: PD-1, PD-L1, Non-small-cell lung cancer, EGFR, Gene mutationIntroduction
Lung cancer, the leading cause of cancer-related deaths,
has the highest incidence and mortality rates amongst all
malignancies worldwide [1]. Lung cancer has an incidence
of over 1.6 million cases/year accounting for 13% of all
new cancer diagnoses and 1.4 million deaths/year account-
ing for 18% of all cancer-related deaths [2,3]. Particularly
in China, both of the incidence and mortality rates of lung
cancer are the highest over the world [4].
Amongst the various types of lung caners, non-small-
cell lung cancer (NSCLC) comprises 80% - 85% of all
cases and more than 70% are diagnosed as unresectable
advanced disease [1,5]. Though much progress has been
obtained in optimizing the treatment of NSCLC, the
prognosis for NSCLC patients remains poor, with the 5-
year overall survival (OS) rate of 15% of all stages [1].
Up to date, the pivot for curing advanced NSCLC has
been the direct inhibition of tumor cell growth by cyto-
toxic agents or targeted small-molecule inhibitors. How-
ever, platinum-based chemotherapy only has a response
rate of 20% - 35% and a median OS of 10–12 months,
while targeted therapy with tyrosine kinase inhibitors
(TKIs) can not prolong OS significantly [6] and moreover* Correspondence: wcpjscz@163.com
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treatment strategies are urgently needed.
Given that cancers are recognized by human immune
system, and under certain circumstances the immune sys-
tem can obliterate tumors [7], many clinical physicians
have considered immunotherapy as a treatment modality
for NSCLC over the last several decades. It has already
been found that chronic inflammation increases neutro-
phils, decreases lymphocytes, and increases cytokine re-
lease and interleukin secretion to reduce cancer cell
apoptosis in lung [8]. Until recently, one promising break-
through that NSCLC responds to immune checkpoint
blockade has emerged, suggesting that NSCLC is an im-
munologically targetable disease.
T cells play pivotal effector-like roles in the complicated
network of human the immune system. T cells hamper
tumor development [9,10] but unfortunately tumors can
also prevent themselves from sustained T cell responses
via so called immune checkpoints like CTLA-4, PD-1 and
PD-L1 etc. [11]. Studies in mouse models have revealed
that manipulation of inhibitory immune checkpoints could
reduce T cell responses against tumors [12]. In additon, we
know that NSCLC induces pro-tumorigenic immunosup-
pressive changes to evade the immune system, and these
changes can be elicited by the inhibitors [13]. So immune
checkpoint inhibitors can restore T cell resoponses and
thus impede the tumor evasion of NSCLC.is an Open Access article distributed under the terms of the Creative Commons
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PD-1, a type 1 transmembrane protein of the Ig superfam-
ily [14], consists of an extracellular N-terminal IgV-like
domain, a transmembrane domain, and a cytoplasmic tail
[15] engaging in inhibitory signal transmission [16]. Being
expressed on activated immune cell types including T
cells, B cells, natural killer (NK) cells, NKT cells, dendritic
cells (DCs), macrophages, and host tissues [17,18], the ex-
pression on effector T cells is associated with constitutive
antigen exposure and thus PD-1 has become a marker of
T cell unresponsiveness or exhaustion [19].
PD-1 has two known ligands, PD-L1 (B7-H1) and PD-
L2 (B7-DC), which belong to B7 family [20,21]. PD-L1 is
the major ligand and expressed on hematopoietic cells in-
cluding T cells, B cells, DCs, macrophages and mast cells
[22] as well as many nonhematopoietic cells including
endothelial cells and numerous epithelial cells [23]. PD-L1
is expressed on many tumors including cancers develop-
ing in various organs such as head and neck, lung, stom-
ach, colon, pancreas, breast, kidney, bladder, ovary, cervix,
as well as melanoma, glioblastoma, multiple myeloma,
lymphoma, and various leukemias [24-28], thereby inhibits
effective anti-tumor immune responses mediated by PD-
1-expressed T cells [11].
PD-1 and PD-1 L interact with each other and then in-
hibit expression of multiple transcription factors of T
cells such as GATA-3 and T-bet [29]. Besides, the PD-1/
PD-L1 interaction inhibits the proliferation, survival, and
effector function of CD8+ cytotoxic T lymphocyte (CTL)
and thus induces apoptosis of tumor-infiltrating T cells
[30]. Ectopic PD-L1 expression in tumor cells in a syn-
geneic transplant model facilitated the escape of the
tumor cells from CTL control [31].
Besides, it was shown that PD-L1 expression plays a crit-
ical role in differentiation of regulatory T cells (Tregs) and
maintaining their suppressive function [32]. Because Tregs
are important inhibitors of tumor-specific immune re-
sponses in the tumor microenvironment, PD-1/PD-L1-
mediated generation of Tregs can help as another layer of
protection to immune evasion of tumors. Therefore, block-
age of PD-1 or PD-L1 can activate the anti-tumor activity
through both effector T cell activation and Treg inhibition.
Additionally, PD-1/PD-L1 interactions can promote the
differentiation of CD4+ T cells into FOXP3+ Tregs [30],
further suppressing the immune system and resulting in
peripheral immune tolerance in cancer patients [33]. As
well, the effects of PD-1 blockade can be mediated partially
by B cells or NK cells. An in vitro study revealed that PD-1
could inhibit stimulating signals of B cell receptors,
leading to restoration of B cell activation after trans-
fecting gene fragments of PD-1 into B lymphoma cell
lines [34]. It has been reported that B cell antigen re-
ceptor signal inhibits B cell proliferation and function
by inducing PD-1 expression [34] and Tumor-producedIL-18 inhibits the function of NK cells via enhancing
PD-1 expression [35].
In gene level, tumor cells can activate PD-L1 expres-
sion of via multiple oncogenic signaling pathways involv-
ing IFN-γ/JAK2/IFN [24], PI3K [36], ALK/STAT3 [37],
MEK/ERK/STAT1 [38], MYD88/TRAF6 [38] or expos-
ure to inflammatory cytokines such as IFN-γ [39] pro-
duced by infiltrating immune cells.
Altogether, PD-L1/PD-1 interation plays an important
role in the reduction of specific T cell apoptosis, inhibition
of immune response to tumors, and immune evasion of
tumors [40]. The inhibition of PD-1/PD-L1 pathway may
hamper the proliferation of activated effector T cell, caus-
ing the tumor evasion from the killing of CTLs, resulting
in the weakening of anti-tumor immune response [41].
PD-L1 blockade for cancer immunotherapy
Given that PD-1 is highly expressed on lymphocytes in-
filtrating human tumors and circulating tumor-specific
T cells [42], and together with that PD-L1 expression is
correlated with prognosis in many cancers, which sug-
gests that PD-L1 expression is a mechanism for tumor
immune evasion [24,28,31], it is reasonable to consider
the blockade of the PD-1/PD-L1 interaction may be a
promising anticancer immunotherapy.
PD-L1 overexpression on mouse mastocytoma models
inhibited tumor-directed T cell cytotoxicity in vitro and
furthermore promoted apoptosis of tumor-specific T
cells and immune evasion, these effects were neutralized
by antibody-mediated blockade of PD-L1 [24,31]. More-
over in several experiments, blockade of PD-L1 could
promote immune-mediated destruction of tumors which
expressed PD-L1 [24,43].
The clinical significance for prognosis of PD-L1 ex-
pression on tumors is controversial, correlating with in-
ferior outcomes in some studies [44-47] and superior
outcomes in others [39]. But the consensus is that there
were no remarkable adverse immune-related events
(irAE) reported in preclinical models of PD-1 or PD-L1
blockade. Overall, therapeutic blockade of PD-1 or PD-
L1 might break these multiple layers of immune inhib-
ition, allowing effective anti-tumor T cell responses.
Studies in NSCLC
PD-1 overexpression on CD8+ T cells in NSCLC sug-
gests a reduced production of various cytokines and T
cell proliferation [48]. Abnormal expression PD-L1 has
been identified in a range of 19% to 100% of NSCLC
tumor cases [49-52], and associated with poor prognosis
[50,51]. On the other hand, PD-L1+ cells are remarkably
increased comparing with adjacent lung parenchyma,
and PD-L1 expression on NSCLC cells also correlates
with poor prognosis and shortened OS [48]. Hence it
can be indicated that blockade of PD-1 interactions
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mentarium of effector function on the NSCLC cells.
To date, a few antibodies which inhibit the PD-1 pathway
by blockade of the PD-1 or PD-L1 have been invented.
Nivolumab
Nivolumab (BMS-936558) is a fully human IgG4 antibody
blocking the PD-1 receptor [53]. Results of a phase I trial
revealed an objective response rate (ORR) of 17% in 129
previously treated patients with advanced NSCLC [54]. Al-
though the median PFS in the cohort was 2.3 months and
the median OS was 9.9 months, these who responded
enjoyed sustained benefits. Specifically, the 2-year OS rate
was 24%, and many remained in remission after complet-
ing 96 weeks of continuous therapy.
The most critical clinical data of nivolumab is from
a phase Ib dose-escalation study enrolling 269 patients
with various advanced solid tumors including NSCLC
[55]. A promising response rate of 18% was observed in
NSCLC patients. Rates of irAE (diarrhea, rash) appeared
to be few and tolerable.
In other studies, nivolumab has also been tested in
combination with platinum for first-line NSCLC, with
an ORR of 33%, and a grade 3 or 4 AE rate of 49%, and
most of AEs were attributable to chemotherapy [56].
In the above trials, patients generally received anti-PD-1
antibody until progression for 1 to 2 years. If study partici-
pants achieved a durable response and then subsequently
progressed after cessation of therapy, there was an oppor-
tunity for rechallenge at the time of progression [57].
Lambrolizumab
Lambrolizumab (MK-3475) is a humanized IgG4 antibody
directed against PD-1 [58]. In a phase I open-label, dose-
escalation study enrolling advanced solid tumor patients,
clinical activity of an unconfirmed partial response was
observed in 1 patient with squamous NSCLC.
BMS-936559 (previously MDX-1105) is a fully human,
PD-L1-specific IgG4 mAb [53]. A phase I study evaluating
its anti-tumor activity reported an ORR of 10% in patients
with NSCLC [59]. No cases of pneumonitis were reported.
Correlation between PD-1/PD-L1 expression and EGFR/
KRAS expression
In the clinical trials mentioned above, only a subset of
patients responded to PD-1 blockade. And NSCLC is a
disease characterized by driver mutation-defined mo-
lecular subsets, each with distinct clinicopathologic fea-
tures and potentials for targeted therapies. Hence, it is
appealing to explore the clinicopathological characteris-
tics and molecular associations of NSCLC expressing
PD-1 or PD-L1, which might be candidates for anti-PD-
1/PD-L1 immunotherapy.As widely known, one of the most commonly mutated
oncogenes in NSCLC patients is EGFR, a member of recep-
tor tyrosine kinases superfamily. EGFR binds to extracellular
ligands, dimerizes with them and auto-phosphorylate [60].
Then, EGFR acts as a key regulatory molecule in cellular
signaling pathways, promoting tumor cell proliferation, in-
vasion and metastasis [61]. EGFR is over-expressed by 40 to
80% of NSCLC, and the expression levels are correlated
with the EGFR tyrosine kinase domain mutations [62].
EGFR tyrosine kinase inhibitors (TKIs) have been devel-
oped for the treatment of advanced NSCLC for years [63].
Unfortunately, only one part of NSCLC patients is sensible
to EGFR-TKIs. Despite the initial response, tumors be-
come TKI-resistant by acquiring either a secondary point
mutation in EGFR (T790M) or additional alterations in
other genes that bypass the requirement for ongoing sig-
naling from the mutated EGFR [64].
Preliminary results have suggested that PD-L1 expression
might be associated with a higher likelihood of response to
PD-1 blockade [65], but reliable biomarkers associated
with treatment response remain poorly known. Activation
of EGFR pathway might be involved in suppressing the
immune response in murine melanoma models either
through activating regulatory T cells or reducing the levels
of the T cell chemoattractant [65]. Besides, other genes
such as KRAS, BRAF and ALK are also important.
The results of the correlation between PD-1/PD-L1
expression and EGFR expression were controversial.
Gettinger et al. concluded that EGFR or KRAS mutation
status did not correlate with response rate of nivolumab
for NSCLC patients [66]. Akbay et al.[67] found that acti-
vation of the EGFR pathway induced PD-L1 expression to
help NSCLC tumors evade from the antitumor immune
response. And it has been observed that EGFR signaling
was independent of its effects on cell proliferation and sur-
vival. D’Incecco et al. [68] observed that PD-1 positive sta-
tus was significantly associated with the presence of KRAS
mutations (P = 0.006), while PD-L1 positive status was
significantly associated with presence of EGFR mutations
(P = 0.001). Patients with PD-L1 positive expression had
higher sensitivity to EGFR-TKIs, longer time to progres-
sion and OS (P = 0.09) than PD-1 negative patients. Mu
et al. observed that in stage I NSCLC patients the rate of
PD-L1 over-expression was 39.9% (65/163) but there was
no significant correlation between PD-L1 expression and
EGFR/KRAS/BRAF/ALK expression [51]. Similarly, Zhang
et al. found that there was no significant relations between
PD-L1 expression and EGFR/KRAS expression in lung
adenocarcinoma [69].
Conclusively, the mentioned genes, not only EGFR,
but also other several genes such as KRAS, BRAF or
ALK, can not be satisfactory biomarkers for assessing
the effects of blockage of PD-1/PD-L1 pathway based on
the results of existing studies.
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Nowadays, the urgent need-to-be solved problems include
the start time point of antibodies using, the duration of
administration, the combination with other treatment mo-
dalities, the identifying of priority population and the over-
coming of antibody resistance [28].
Referring to the combination with other treatment mo-
dalities, the distinct molecular and cellular mechanisms
whereby CTLA-4 and PD-1 suggest that combined thera-
peutic strategy of these pathways might be synergistic for
cancer immunotherapy. Preclinical models of combined
CTLA-4 and PD-1 blockade have shown promising results
without a significant increase in toxicity [70]. The clinical
activity of checkpoint-blocking antibodies in the mono-
therapy setting is established, and the following step is to
assess the safety and activity of combinations.
One noticeable point is that the therapeutic mechan-
ism of PD-1/PD-L1 targeted therapy is different from
chemotherapy and present molecular targeted therapies.
Hence, novel assessment criteria for therapeutic effects
are needed. We have proposed a preliminary evalation
system for the effect of another widely used antitumor
immunotherapy, cytokine-induced killer cell therapy
[71], and the system for PD-1/PD-L1 targeted therapy is
presumed to be similar to some extent.
Furthermore, the relative contributions of T cells, B
cells, NK cells, NKT cells, DCs, and macrophages to the
anti-cancer activity of PD-1 blockade should be clarified
more deeply, as PD-1 is expressed on all of these types
of immune cells.
Conclusively, PD-1 and PD-L1 are important check-
points in tumor development. PD-1/PD-L1 pathway is a
promising target for treating NSCLC, and its correlation
with EGFR/KRAS mutation needs confirmation by pro-
gressive studies.
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